Literature DB >> 34570362

Severe 5-Fluorouracil-Associated Gastrointestinal Toxicity Unexplained by Dihydropyrimidine Dehydrogenase Deficiency and Renal Impairment: Should We Be Investigating Other Elimination Pathways to Assess the Risk of 5-Fluorouracil Toxicity?

Soo Hee Jeong1, Ottiniel Chavani2, Kathryn Burns3, David Porter4, Michael Findlay4,5, Nuala Helsby3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34570362     DOI： 10.1007/s13318-021-00721-0

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN： 0378-7966            Impact factor:   2.441


× No keyword cloud information.
  4 in total

1.  Interindividual variation in expression of P-glycoprotein in normal human liver and secondary hepatic neoplasms.

Authors:  E G Schuetz; K N Furuya; J D Schuetz
Journal:  J Pharmacol Exp Ther       Date:  1995-11       Impact factor: 4.030

2.  [Biliary and pancreatic excretion of methotrexate (MTX) and 5-FU on the MTX/5-FU sequential therapy].

Authors:  Y Suda; S Akazawa
Journal:  Gan To Kagaku Ryoho       Date:  1990-07

3.  Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile.

Authors:  G D Heggie; J P Sommadossi; D S Cross; W J Huster; R B Diasio
Journal:  Cancer Res       Date:  1987-04-15       Impact factor: 12.701

4.  A case-control study to assess the ability of the thymine challenge test to predict patients with severe to life threatening fluoropyrimidine-induced gastrointestinal toxicity.

Authors:  Nuala A Helsby; John Duley; Kathryn E Burns; Claire Bonnet; Soo Hee Jeong; Elliott Brenman; Paula Barlow; Katrina Sharples; David Porter; Michael Findlay
Journal:  Br J Clin Pharmacol       Date:  2019-12-12       Impact factor: 4.335
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.